Fierce Biotech

Instil's stock sinks after it clears out pipeline, hands 2 drugs back to ImmuneOnco

By ending its agreement with ImmuneOnco, Instil is also handing back the other asset from the licensing deal: IMM27M, a next-gen anti-CTLA-4 antibody that ImmuneOnco had taken into phase 1 trials as a ...

Instil Bio Pulls Plug On Lead Drug Development

Instil Bio stock falls after the company ends development of its lead cancer drug and exits a licensing deal, raising new ...

Instil Bio Discontinues Clinical Development of AXN-2510, Ends Agreement with ImmuneOnco

Instil Bio said its subsidiary has discontinued clinical development of AXN-2510 and terminated its collaboration agreement with ImmuneOnco Biopharmaceuticals (Shanghai) for AXN-2510 and AXN-27M.

Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco

Instil Bio, Inc. (Nasdaq: TIL) (“Instil”) today announced that Axion Bio, Inc. (“Axion”), a wholly-owned subsidiary of Instil ...
BioPharma Dive

Arrowhead showcases early obesity data; Instil bails on PD-1/VEGF drug

Arrowhead’s RNA drugs could aid with “high-quality” weight loss, according to one analyst. Elsewhere, the PD-1/VEGF field got ...
Investing.com South Africa

Instil Bio stock falls after subsidiary discontinues AXN-2510 development

Investing.com -- Instil Bio (NASDAQ:TIL) stock fell 15% Tuesday after the company announced that its wholly-owned subsidiary Axion Bio has decided to discontinue clinical development of AXN-2510 and ...
WRIC

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed ...

Anticipate ImmuneOnco sharing initial safety and efficacy results from phase 2 trial of ‘2510 + chemo in 1L NSCLC in the second half of 2025 DALLAS, July 02, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. ...
Seeking Alpha

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a ...

DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (TIL) (Nasdaq: TIL, “Instil”) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code ...
Yahoo Finance

Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?

If you're an investor looking for stocks that can make dramatic gains in a short amount of time, you may have noticed a small-cap biopharmaceutical company called Instil Bio (NASDAQ: TIL) has been ...
Seeking Alpha

Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting

DALLAS, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of ...
Nasdaq

Instil Bio, Inc. Progresses with Ongoing NSCLC Trials for AXN-2510/IMM2510 and Reports Q1 2025 Financial Results

Instil Bio reports ongoing trials for AXN-2510/IMM2510 in NSCLC; financial results show cash reserves enabling operations beyond 2026. Instil Bio, Inc. announced ongoing enrollment for a clinical ...
Nasdaq

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a ...

DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, “Instil”) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced a ...